LivsMed

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • USD 10% exchange rate change impacts pre-tax profit by -KRW 13,769K at year-end 2025, down from ±KRW 49,286K at 2024 year-end
• • Total allowance for doubtful accounts on trade receivables KRW 1,170M at 2025 year-end, nearly doubled from KRW 594M a year ago

Management Discussion & Analysis

• • Revenue KRW 51,192M (+88.8% YoY from KRW 27,121M); operating loss KRW 22,642M (-14.6% YoY from KRW -26,504M)
• • Domestic market penetration of core product ArtiSential drove revenue growth, supported by increased sales and gross profit

Business Overview

• • Minimally invasive laparoscopic surgery instruments sales with ArtiSential 5mm and 8mm shaft products; 2025 sales KRW 49.6B (96.9% of total)
• • Launched ArtiSeal multi-joint vessel sealer with 90° rotation; approved domestically (2023) and US, Japan (2024), EU CE MDR in early 2025; KRW 1.58B sales in 2025

What are the latest LivsMed DART filings in 2026?

LivsMed (KRX code 491000) has filed an annual report on March 23, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did LivsMed file its most recent annual report?

LivsMed filed its most recent annual report on March 23, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is LivsMed's KRX stock code?

LivsMed's KRX stock code is 491000. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 491000 to look up all LivsMed disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does LivsMed file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for LivsMed.

Where can I find LivsMed financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from LivsMed annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.